Media headlines about Nuvectra Corporation (NASDAQ:NVTR) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nuvectra Corporation earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8108067528442 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Nuvectra Corporation (NASDAQ:NVTR) last released its earnings results on Tuesday, August 8th. The company reported ($1.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.14) by $0.07. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $5.96 million. During the same period last year, the company posted ($0.85) EPS. The business’s revenue was up 188.0% on a year-over-year basis.
Several equities research analysts have weighed in on NVTR shares. TheStreet raised Nuvectra Corporation from a “d” rating to a “c-” rating in a research note on Monday, June 19th. Zacks Investment Research raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. ValuEngine raised Nuvectra Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Finally, Piper Jaffray Companies reissued a “neutral” rating and set a $14.00 price objective on shares of Nuvectra Corporation in a research note on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $13.00.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.truebluetribune.com/2017/10/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-nuvectra-corporation-nvtr-share-price.html.
In other news, CEO Scott F. Drees purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $11.72 per share, for a total transaction of $117,200.00. Following the acquisition, the chief executive officer now directly owns 125,180 shares of the company’s stock, valued at $1,467,109.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.60% of the stock is owned by company insiders.
About Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.